Robert Lee Page II, PharmD, MSPH, FCCP, FAHA, FASCP, BCPS
Associate Professor of Clinical Pharmacy & Physical Medicine
Clinical Specialist, Division of Cardiology
University of Colorado, School of Pharmacy and Medicine
Jack E. Ansell, MD
Department of Medicine
Lenox Hill Hospital
New York, NY
THIS ACTIVITY WAS ORIGINALLY PRESENTED AS A LIVE AUDIOCONFERENCE SERIES BEGINNING NOVEMBER 23, 2009. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE AUDIOCONFERENCE, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.
Venous thromboembolism (VTE) is a major health problem in the United States. About 600,000 cases occur each year, and the incidence continues to increase as the population ages. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are the most serious forms of VTE. DVT causes multiple complications and may lead to PE, which is often fatal. About 25% of patients die within 7 days after their first VTE, and in 22% of VTE patients, death occurs so rapidly there is no time for intervention.
The risk of VTE is substantial in long-term care (LTC) settings. Skilled nursing residents are at 8 times greater risk for VTE than individuals residing outside of nursing homes. Patients in LTC often have medical conditions that warrant anticoagulant prophylaxis or treatment, including DVT and PE. Nursing home confinement has been identified as one of the independent risk factors for VTE, yet in this clinical setting prophylaxis is seldom provided. This gap in clinical care indicates clinicians need further education on VTE in LTC residents so they can identify individuals at risk and initiate appropriate treatment.
This activity provides continuing education on how to risk-stratify and manage patients at risk for VTE. These skills, along with increased knowledge on prophylactic therapy, are needed to improve outcomes in LTC settings.
This continuing education is designed for long-term care providers, including consultant pharmacists, physicians, nurse practitioners, and nurses.
Upon completion of this knowledge-based, educational activity, the participant should be able to:
Evaluate strategies to risk-stratify patients for VTE in LTC settings.
Select appropriate prophylactic agents for those at high risk for VTE in LTC settings.
Compare the risk to benefit ratio of available anticoagulant agents for preventing VTE in LTC residents.
Determine the appropriate duration of therapy in patients with VTE.
Discuss the interdisciplinary team approach to caring for patients at risk for VTE.
It is the policy of ASCP, in accordance with the standards set forth by the Accreditation Council for Pharmacy Education, and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any relevant financial relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by ASCP and AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial interests to disclose.
The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker¹s interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Robert Lee Page II, PharmD, FCCP, FAHA, BCPS, CGP, has no conflicts of interest to disclose.
Jack E. Ansell, MD, receives consulting fees from Bayer, Ortho-McNeil, Pfizer, and Bristol-Myers Squibb; research funding from Ortho-McNeil, and participates on the speakers’ bureau for sanofi-aventis.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
Pharmacists: The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity (UAN: 203-999-09-100-H01-P) was developed by ASCP and is approved for 1.0 Contact Hour (0.1 CEU).
Nurses: NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation #1088. This program provides 1 contact hour by NADONA/LTC.
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurse Practitioners: AKH Inc. is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. AKH Inc. designates this educational activity for 1.0 contact hour.
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit. A statement of credit will be available immediately if the post-test and evaluation are completed online.
Commercial Support Statements
Supported by an educational grant from sanofi-aventis U.S.